Abstract: A method for objectively quantitating the cellular infiltration in a tissue biopsy of a warm-blooded animal using a capture ELISA method. This method also allows one to quantitate the cellular infiltration of a tissue biopsy corresponding to an inflammatory response. As such this invention has both research and clinical applications in the analysis of an inflammatory response, and the effectiveness of immunosuppresants in addressing the inflammation.

Abstract: The present invention relates to pigment mixtures containing at least two components, component A being Al2O3 flakes coated with one or more metals, metal oxides and/or metal sulfides and component B being special-effect pigments, and to their use in varnishes, paints, printing inks, masterbatches, plastics and cosmetic formulations.

Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

Abstract: Cyclohexapeptidyl amine compounds are disclosed of the formula: or its acid addition salt, wherein: R1 is H or OH; R2 is H or OH; R3 is QCnH2nNRVRVI, QCnH2nNRVRVIRVII+Y−, or Q(CH2)1-3CRVIIIRIXNHRX.

Abstract: The present invention provides for the combined use of 5&agr;-reductase inhibitors together with calcium channel blockers for the treatment of benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, hematuria, and other androgen related disorders, including prostatitis and the prevention of prostate cancer. This invention provides a method of treatment which is useful in the treatment of benign prostatic hyperplasia, prostatitis, and/or the prevention and treatment of prostatic cancer, as well as in the treatment of prostatitis and hematuria. This invention also provides a pharmaceutical composition which is useful in the treatment of benign prostatic hyperplasia, prostatitis, hematuria and/or the prevention and treatment of prostatic cancer, wherein the pharmaceutical composition comprises the combination of a 5&agr;-reductase inhibitor and a calcium channel blocking agent.

Abstract: The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: The invention relates to a process for preparing perfluoroalkylfluorophosphoranes of the general formula (CnF2n+m)yPF5−y  (I) where n is 1, 2, 3, 4, 5, 6, 7 or 8 m is +1 or −1 and y is 1, 2 or 3, where the ligands (CnF2n+m) may be identical or different, and also to their use as electrolytes and as precursors for conducting salts, and to their employment in lithium batteries.

Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.

Abstract: The present description relates to a roller wash composition for the cleaning of the cylinder, polymer plate and other soiled parts of printing machines when using water-based printing inks.

Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenem antibacterial agents are disclosed.

Abstract: The invention relates to a process for preparing an optical retardation film comprising at least one layer of an anisotropic polymer material, to a method of rubbing a substrate for the alignment of liquid crystal or mesogenic material that can be used in the above process, to an optical retardation film obtainable by the above process, to the use of such an optical retardation film in a liquid crystal display, and to a liquid crystal display device comprising a liquid crystal cell and such an optical retardation film.

Abstract: A method for treating Pediculosis capitis infestation in a human patient which comprises orally administering to the human a total amount of ivermectin of between about 400 ug/kg and about 1200 ug/kg over a period of time of about one week, wherein equal portions of the total amount are administered according to an administration sequence selected from the group consisting of c) a first day and a second day, and d) a first day, a second day and a third day, during the one week time period. The invention is also a method for treating Pediculosis capitis infestation in a human patient which comprises orally administering to the human a total amount of ivermectin of between about 6 mg and 135 mg over a period of time of about one week, wherein equal portions of the total amount are administered according to an administration sequence selected from the group consisting of e) a first day and a second day, and f) a first day, a second day and a third day, during the one week time period.

Abstract: Sulfur-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: A pharamceutical composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein A is C1-6alkyl, C2-6alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, arylC1-6alkyl, aryl, S(O)pR1.

Abstract: A novel process is provided for the preparation of 3-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-propylamine which is useful in the synthesis of &agr;v integrin receptor antagonists. Also provided are useful intermediates obtained from the process.

Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.

Abstract: Piperazine derivatives of the formula I in which R1 and R2 have the meanings given in claim 1 are dopamine ligands with a selectivity for the D4 receptor and are suitable for the treatment and prophylaxis of states of anxiety, depression, schizophrenia, obsessions, Parkinson's disease, tardive dyskinesia, nausea and disorders of the gastro-intestinal tract.

Abstract: A recombinant human neurokinin-3 receptor (hereinafter identified as human NK3R) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK3R complementary DNA; expression systems, including a CHO (chinese hamster ovarian cell line) stable expression system; and an assay using the CHO expression system. Human NK3R can be used in an assay to identify and evaluate entities that bind to the neurokinin-3 receptor.

Abstract: Described are compound of the formula (I) defined herein which are useful, for example, in the treatment of diabetes. Also described is a method for preparing the compounds.

Abstract: Liquid crystal phases containing components of the formulae I and III have an acceptable combination of threshold steepness, viewing angle and temperature dependence at a low threshold voltage.